Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News
  • Price Target

Wells Fargo Downgrades Edwards Lifesciences to Equal-Weight, Lowers Price Target to $78

By Benzinga Newsdesk
Today, 4:06 PM
Wells Fargo analyst Larry Biegelsen downgrades Edwards Lifesciences (NYSE:EW) from Overweight to Equal-Weight and lowers the price target from $97 to $78.

EW

Read More
1 minute read
  • Analyst Ratings
  • Downgrades
  • News

Raymond James Downgrades Edwards Lifesciences to Market Perform

By Benzinga Newsdesk
Today, 4:06 PM
Raymond James analyst Jayson Bedford downgrades Edwards Lifesciences (NYSE:EW) from Outperform to Market Perform.

EW

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Canaccord Genuity Maintains Hold on Edwards Lifesciences, Raises Price Target to $76

By Benzinga Newsdesk
Today, 4:06 PM
Canaccord Genuity analyst William Plovanic maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target from $68 to $76.

EW

Read More
1 minute read
  • Earnings
  • Earnings Beats
  • General
  • Guidance
  • Health Care
  • Large Cap
  • News

Edwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023

By Vandana Singh
Today, 4:06 PM
Edwards Lifesciences Corp (NYSE:EW) reported Q4 adjusted EPS of $0.64, up 25% Y/Y and higher than the consensus of $0.61.…

EW

Read More
1 minute read
  • Guidance
  • News

Edwards Lifesciences Sees FY23 Sales $5.6B-$6B Vs $5.78B Est; Q1 2023 EPS $0.58-$0.64 Vs $0.59 Est; Q1 2023 Revenue $1.37B-$1.45B Vs $1.37B Est

By Happy Mohamed
Today, 4:06 PM
Outlook Overall, the company is reaffirming the sales guidance it provided at the December investor conference for all product groups.  Full year 2023 sales are expected to grow 9 to 12

EW

Read More
1 minute read
  • Dividends
  • Earnings
  • News

Here’s How Much $1000 Invested In Edwards Lifesciences 10 Years Ago Would Be Worth Today

By Benzinga Insights
Today, 4:06 PM
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 10 years by 7.79% on an annualized basis…

EW

Read More
5 minute read
  • Earnings

Earnings Scheduled For January 31, 2023

By Benzinga Insights
Today, 4:06 PM
Companies Reporting Before The Bell • Biophytis (NASDAQ:BPTS) is projected to report earnings for its first quarter.

ALGM

Read More
2 minute read
  • Analyst Ratings

What 8 Analyst Ratings Have To Say About Edwards Lifesciences

By Benzinga Insights
Today, 4:06 PM
Over the past 3 months, 8 analysts have published their opinion on Edwards Lifesciences (NYSE:EW) stock. These analysts…

EW

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Morgan Stanley Maintains Overweight on Edwards Lifesciences, Raises Price Target to $95

By Benzinga Newsdesk
Today, 4:06 PM
Morgan Stanley analyst Cecilia Furlong maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $92 to $95.

EW

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • General
  • Health Care
  • Long Ideas
  • Markets
  • News
  • Small Cap
  • Trading Ideas

Jim Cramer Recommends These 5 Healthcare Stocks For 2023: ‘Biggest Winners Were Boring, Consistent Operators’

By Bhavik Nair
Today, 4:06 PM
Prominent market commentator Jim Cramer has recommended five healthcare stocks which he believes should be on investors’ shopping list for 2023.

BHVN

Posts navigation

1 2 … 17 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service